SCHEDULE: KI Holdings Acquires Stake in Hepion Pharmaceuticals

KI Holdings Ltd., through Donald Kivowitz, has acquired a 10.2% stake in Hepion Pharmaceuticals, Inc. via a private placement involving common stock and warrants.

Summary

• KI Holdings Ltd., associated with Donald Kivowitz, has acquired 10,000,000 shares of Hepion Pharmaceuticals, Inc. common stock, representing a 10.2% ownership stake.
• The acquisition occurred on August 3, 2026, through a Securities Purchase Agreement dated July 31, 2026.
• In addition to the shares, KI Holdings Ltd. also purchased one warrant to acquire an additional 10,000,000 shares at $0.06 per share.
• The total purchase price for the shares and warrant was $500,000, funded by KI Holdings Ltd.'s working capital.
• The Reporting Persons intend to review their investment and may adjust their position based on market conditions and the company's performance.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the dilutive nature of the capital raise and the current stage of the company's development, though the investment itself is a positive sign of confidence.

Positives

• Significant investment of $500,000 by KI Holdings Ltd. into Hepion Pharmaceuticals.
• Acquisition of a 10.2% ownership stake, indicating substantial investor confidence.
• Warrant provides potential for further investment and increased ownership at a fixed price.

Negatives

• The issuance of new shares and warrants could be dilutive to existing shareholders.
• The purchase price of $0.06 per share for the common stock is relatively low, potentially reflecting current market valuation.
• The warrant exercise price of $0.06 per share is also low, suggesting a belief that the stock price may not significantly appreciate in the short term.

Risks

• The company's future prospects and stock performance are subject to market conditions, its business performance, and general economic factors.
• Potential for further dilution if the warrants are exercised.
• The 'Beneficial Ownership Limitation' in the warrant could restrict the ability to exercise it fully.

Future Outlook

The Reporting Persons intend to continuously review their investment in Hepion Pharmaceuticals. Depending on market conditions, the company's business, financial condition, prospects, and other factors, they may acquire additional securities, dispose of existing securities, or maintain their current investment position. No specific future plans beyond this review are currently disclosed.

Management Comments

• Donald Kivowitz is a business executive and investor.
• KI Holdings Ltd. is an investment holding company.

Industry Context

StockSavvy.ai notes that this filing indicates a significant private investment into a biopharmaceutical company, a sector often characterized by high risk and high reward. The terms of the investment, particularly the low exercise price of the warrant, suggest the investor may be anticipating a turnaround or significant growth, but also acknowledges the current valuation challenges common in early-stage or development-focused biotech firms.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new shares and warrants. The investment may also signal confidence, potentially impacting share price positively in the long term.
• Creditors: No direct impact mentioned, but a stronger financial position from capital infusion could be beneficial.
• Employees: Continued funding supports ongoing operations and development, potentially securing employment.
• Suppliers: Stable operations supported by new capital can ensure continued business relationships.

Next Steps

• KI Holdings Ltd. will continue to review its investment in Hepion Pharmaceuticals.
• Depending on various factors, KI Holdings Ltd. may acquire more shares, sell shares, or hold its current position.

Key Dates

Recommendation

The filing indicates a significant investment, which is a positive signal. However, the dilutive nature of the capital raise and the low exercise price of the warrants suggest that the immediate upside may be limited, and the company's future performance is still subject to considerable risk. A 'hold' position allows for further observation of the company's progress and the impact of this investment.

Keywords

Hepion Pharmaceuticals, KI Holdings Ltd., Donald Kivowitz, Schedule 13D, Securities Purchase Agreement, Private Placement, Warrant, Investment